AUG 1 5 2003

Flease type a plus sign (+) inside this box →

G:

08-18-03

1646-

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM				Application Number	09/819,094		
				Filing Date	March 27, 2001		
			-	First Named Inventor	WEINER, RICHARD I.		
				Group Art Unit	1646		
	(to be used for all correspondence after initial filing)			Examiner Name	BRANNOCK, MICHAEL T.		
	Total Number of Pages in This Submission			Attorney Docket Number	UCSF-264CON		
ENCLOSURES (check all that apply)							
	Extension of Tone Express Aband Information Dis Certified Copy Documents Response to Management Incomplete Ap	ched Reply al s/declaration(s) ime Request donment Request sclosure Statement of Priority //issing Parts/ plication	Assign (for an Drawir Licens Petitio Petitio Provis Power Chang Addres Termir Reque	ament Papers Application) ag(s) ing-related Papers n to Convert to a ional Application of Attorney, Revocation in the Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): copy of Original Declaration; Copy of Supplemental Declaration; postcard		
	Response to Missing Parts under 37 CFR 1.52 or 1.53		AUG 2 1 2003				
		JECH CENTER 1600/2900					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Signing Attorney/Agent (Reg. No.) KARL BOZICEVIC, BOZICEVIC, FIELD			/				
Signature			/ / hycin				
Date		August 15, 2008					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXPRESS MAIL LABEL NO. EV 333 999 296 US

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AUG 1 5 2003

EXPRESS MAIL LABEL NO.EV 333 999 296 US

AMENDMENT	UNDER
37 C.F.R. §1	.116

Address to:
Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

IL LABEL NO.E V 333 999 290 US				
Attorney Docket	UCSF-264CON			
Confirmation No.	1646			
First Named Inventor	WEINER, RICHARD			
Application Number	09/819,094			
Filing Date	March 27, 2001			
Group Art Unit	1646			
Examiner Name	BRANNOCK, MICHAEL T			
Title	NOVEL ANTIANGIOGENIC			
	PEPTIDE AGENTS AND			
	THEIR THERAPEUTIC AND			
	DIAGNOSTIC USE			

Sir:

This amendment is responsive to the Final Office Action dated May 19, 2003 for which a three-month period for response was given making this response due on or before August 19, 2003. In view of the amendments to the claims and the remarks put forth below, reconsideration and allowance are respectfully requested.

Applicants submit that the amendments set forth below raise no new issues. Rather, the amendments place the claims in form for allowance or in better form for appeal. Entry of these amendments is thus respectfully requested.

Applicants note that those claims not amended herein are being reiterated solely for the convenience of the Examiner.